In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche to gain full ownership of Genentech in $43.7bn deal

Executive Summary

Aiming to gain full ownership of the Top Biotech that has brought it much success in the cancer drug market, Roche intends to acquire the 44.1% of outstanding shares and options of Genentech (publicly traded) it doesn't already own for approximately $43.7bn. Roche says the deal would create the seventh-largest pharmaco by market share in the US, producing over $15bn in annual revenues.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Partial Acquisition
    • Payment Includes Cash

Related Companies